Antibody therapies

Glennie MJ, Johnson PWM (2000) Clinical trials of antibody therapy. Immunol Today 21(8) 403—410... 

Taylor PC (2003) Antibody therapy for rheumatoid arthritis. Current Opin Pharmacol 3 323-328... 

Interpret the current role for monoclonal antibody therapy in non-Hodgkin s lymphoma. 

The next hypothesis tested was whether combining monoclonal antibody therapy with chemotherapy could increase... 

McCune SL, Gockerman JP, Rizzieri DA. Monoclonal antibody therapy in the treatment of non-Hodgkin s lymphoma. JAMA 2001 286 1149-1152. 

McLaughlin P, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma Half of patients respond to a four dose treatment program. J Clin Oncol 1998 16 2825-2833. 

Treatment primarily consists of supportive care. Ventilate patient if they have difficulty breathing and administer oxygen. Be prepared to treat for shock. Monitor and support cardiac and respiratory functions as necessary. If the identity of the toxin is known, administer antidote if available. Unlike chemical agents, toxins can cause an immune response. Vaccines are available for some toxins but generally require more than 4 weeks for the body to produce antibodies. Passive immunotherapy is effective for some neurotoxins but must be instituted shortly after exposure. The utility of antibody therapy drops sharply at or shortly after the onset of the first signs of disease. 

O Mahony, D. and Bishop, M. 2006. Monoclonal antibody therapy. Frontiers in Bioscience 11, 1620-1635. 

Caution The death rate from untreated pneumonic plague can reach almost 100 percent. Once a human is infected with plague, a progressive and potentially deadly illness usually results unless antibody therapy is administered. In a progressional sequence, the patient develops blood infection which leads to lung infection. 

Bonner, J.A. et al., Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck a phase III study of high dose radiation therapy with or without cetuximab, Proc. Am. Soc. Clin. Oncol., 22, 489S, Abstr. 5507, 2004. McLaughlin, R et al., Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma half of patients respond to a four-dose treatment program, /. Clin. Oncol., 16, 2825-2833, 1998. 

Maloney, D.G., Grillo-Lopez, A.J., White, C.A., Bodkin, D., Schilder, R.J., Neidhart, J.A., Janakiraman, N., Foon, K.A., Liles, T.-M., Dallaire, B.K., Wey K., Royston, I., Davis, T., and Levy, R., IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin s lymphoma. Blood, 90, 2188-2195, 1997. 

Adams GP, Weiner LM. Monoclonal antibody therapy of cancer, Nature Biotechnology 23 1147-1157 (2005). 

Numerous problems in the construction of chnically applicable drug targeting moieties still need to be solved. Of these issues, immunogenicity after repeated administration, counterproductive hver clearance, and production 5delds are the most important. Although the problem of immunogenicity is beheved to have been solved for monoclonal antibody therapy by the development of humanized and fully human antibodies [110], for other carrier systems such as modified plasma proteins and peptide modified polymers, this remains an important issue. 

While no biopharmaceutical is approved with the requirement of genotyping as a part of its therapeutic indication, a recently approved monoclonal antibody therapy against breast cancer, trastuzumab (Herceptin), is indicated only for those tumors measurably expressing the protein expressed by the gene erbB-2. Because the oncogene product of erbB-2 is elevated... 

Impact of Polymorphisms on the Clinical Outcomes of Monoclonal Antibody Therapy Against Hematologic Malignancies... 

There are two major factors predisposing to resistance to monoclonal antibody therapy. One is a tumor-related factor such as antigen loss, complement resistance antigen expression, intrinsic resistance, or tumor burden. Besides tumor-related factors, growing evidence has indicated that patient-related factors may account for the different responses of the patients to monoclonal antibody therapy. For example, differences in ADCC or CDC function according to individuals may increase our understanding of... 

Villamor N, Montserrat E, Colomer D. Mechanism of action and resistance to monoclonal antibody therapy. Semin Oncol2003 30 424 33. 

---